论文部分内容阅读
目的观察吡格列酮对2型糖尿病患者血压、超敏C反应蛋白和肾功能的影响。方法 72例24h尿白蛋白排泄量(UAE)在30～300mg的2型糖尿病患者在常规降糖治疗的同时随机分为治疗组(吡格列酮30mg/d)36例和对照组36例,疗程24周,分别观察治疗前后2组空腹血糖(FBS)、餐后2h血糖(2h PBG)、糖化血红蛋白(HbA1c)、血压(BP)、血尿素氮(BUN)、血肌酐(Cr)、超敏C反应蛋白(us-CRP)和24h UAE的变化,并计算内生肌酐清除率(Scr)。结果治疗组治疗前后FBS、2h PBG、HbA1c、BP、BUN、us-CRP和24hUAE显著下降(P<0.01),Scr显著上升(P<0.01);对照组FBS、2h PBG、HbA1c明显下降(P<0.05),BP、BUN、Scr、us-CRP24h和UAE无差异性(P>0.05);2组间治疗后比较差异具有显著性(P<0.01)。结论吡格列酮不但能够降低2型糖尿病患者的血压、超敏C反应蛋白,而且对患者的肾功能具有保护作用。
Objective To observe the effects of pioglitazone on blood pressure, high-sensitivity C-reactive protein and renal function in type 2 diabetic patients. Methods 72 patients with 24-urinary albumin excretion (UAE) 30 ~ 300mg type 2 diabetes mellitus were randomly divided into treatment group (pioglitazone 30mg / d) and control group (n = 36) The levels of fasting blood glucose (FBS), postprandial 2h PBG, HbA1c, blood pressure (BP), blood urea nitrogen (BUN), serum creatinine (Cr) (Us-CRP) and 24h UAE changes, and calculate the creatinine clearance rate (Scr). Results The levels of FBS, PBG, HbA1c, BP, BUN, us-CRP and 24hUAE in treatment group decreased significantly (P <0.01) and Scr increased There was no significant difference between the two groups (P> 0.05). There was no significant difference between BPH, BUN, Scr, us-CRP24h and UAE (P> 0.05). Conclusion Pioglitazone can not only reduce the blood pressure and hypersensitive C-reactive protein in patients with type 2 diabetes mellitus, but also have a protective effect on the renal function of patients.